What Happened

Novadip Biosciences, a Belgian late-stage clinical biotech, has closed a €10.4 million convertible financing round. The round was led by US-based New Science Ventures, with participation from existing investors including FundPlus, Wallonie Entreprendre, VIVES Partners, ORSA, Sambrinvest, Noshaq, and invest.bw.

The funds will be used to advance NVD003 through its pivotal Phase 3 program in congenital pseudarthrosis of the tibia and to prepare for regulatory submission in the United States. This financing also supports unlocking a tranche from the European Investment Bank.

Who Is Affected

Novadip's clinical and regulatory teams will directly manage the Phase 3 program and US submission, requiring external partners for trial management, data collection, and regulatory affairs. The company's US market entry will also create demand for compliance and quality assurance services.

Existing and new service providers in the biotech ecosystem—including CROs, clinical trial software vendors, and regulatory consultants—are positioned to support Novadip's expanded operations.

Market Impact

This funding signals continued investor confidence in regenerative medicine and late-stage clinical assets, potentially attracting more capital to the sector.

• Increased demand for clinical trial management and data services as Phase 3 enrollment scales.
• Regulatory consulting needs will rise as Novadip prepares for US FDA interactions.
• Competitors in the congenital pseudarthrosis space may accelerate their own development timelines.

What to Watch

Monitor Novadip's progress in completing the Phase 3 program and any announcements regarding US regulatory meetings or trial milestones. The unlocking of the EIB tranche could signal additional funding rounds or partnerships.

Also watch for new vendor contracts or service provider announcements, which may indicate where Novadip is outsourcing key functions.

Related coverage

• BrainChild Bio raises $116M Series A for CAR-T therapies
• Moonwalk Biosciences Raises $70M Series B for RNAi Obesity Therapies
• Superluminal raises $60M Series B for obesity drug
• Elucid Raises $55M Series D to Expand AI Heart Care Platform